FMTC is caused by pathogenic germline variants in the RET proto-oncogene, located on chromosome 10 per gene location data in this packet. As documented in GeneReviews, all subtypes of MEN2 — including FMTC — are inherited in an autosomal dominant pattern, meaning that a single pathogenic copy of the RET gene is sufficient to confer disease risk; each child of an affected individual has approximately a 50% probability of inheriting the pathogenic variant. GeneReviews notes that penetrance of some RET pathogenic variants is incomplete, such that not all carriers will develop disease, and that the incidence of MTC varies by MEN2 phenotype. Specific genotype-phenotype correlations have been documented in GeneReviews: pathogenic variants at cysteine codons 609, 611, 618, and 620 in exon 10 of the RET gene are detected in approximately 10% of MEN2A families and more than 50% of families with FMTC, and are associated with lower transforming activity of the encoded protein. Variants at codon 634 are more characteristic of MEN2A and carry a higher incidence of pheochromocytoma and parathyroid involvement. In contrast to FMTC, sporadic MTC is associated with a somatic RET pathogenic variant — not a germline alteration — in approximately 40 to 50% of affected individuals, as described in GeneReviews; such somatic changes are not heritable and do not occur in other family members.

As described in GeneReviews, FMTC is suspected in families in which more than one individual has been diagnosed with MTC in the absence of pheochromocytoma or parathyroid adenoma and hyperplasia. Published clinical practice guidelines for the MEN2 spectrum, referenced in GeneReviews, provide a diagnostic framework. Biochemical evaluation includes measurement of plasma calcitonin, plasma carcinoembryonic antigen (CEA), and fractionated metanephrines — the latter to differentiate FMTC from MEN2A. Serum calcium and parathyroid hormone are also assessed during the initial evaluation. Germline RET molecular genetic testing is central to diagnosis and enables presymptomatic identification of at-risk family members. Neck imaging characterizes thyroid lesions and evaluates lymph node involvement, while CT imaging of the chest and abdomen is used to evaluate for metastatic disease in individuals with confirmed MTC, as outlined in GeneReviews management tables. Histopathologic examination of thyroid tissue confirms the MTC diagnosis, and C-cell hyperplasia may be identified as a precursor finding in carriers who have not yet developed invasive malignancy.

No therapies appear in the approved treatments field for FMTC in this data packet. Clinical practice guidelines for the MEN2 spectrum, referenced in GeneReviews, provide a management framework directed by a multidisciplinary endocrine oncology team. Thyroid surgery is the primary documented therapeutic modality; GeneReviews describes prophylactic thyroidectomy in confirmed RET germline variant carriers as a risk-reduction strategy outlined in published clinical guidelines, with timing of surgery guided by the specific RET codon variant and associated risk level. For individuals with locally advanced or metastatic disease, GeneReviews references systemic treatment approaches using kinase inhibitor-class agents; major professional guidelines include consideration of clinical trial participation as an option for individuals who progress on initial systemic therapy. No specific drug names from the GeneReviews text are carried into this narrative, as none appear in the approved treatments field of this packet. Treatment intent ranges from curative where surgical resection is feasible to disease control in advanced or metastatic presentations, with decisions individualized to the patient's clinical stage and overall health status.

The natural history specific to FMTC is not individually certified in this data packet. As documented in GeneReviews, the presence of cervical lymph node metastases at the time of diagnosis — observed in up to 70% of individuals presenting with a palpable thyroid mass or diarrhea — carries significant prognostic relevance. Diarrhea as a presenting symptom, arising from high plasma calcitonin concentrations, implies a poor prognosis as described in GeneReviews. Individuals identified through genetic surveillance before clinical disease development may have more favorable outcomes due to the availability of prophylactic surgical intervention prior to lymph node involvement. Overall prognosis depends on stage at diagnosis, adequacy of initial surgical resection, and the presence or absence of distant metastatic spread, with lymph node status and calcitonin doubling time serving as recognized prognostic determinants.

Several certified active trial records are documented for familial medullary thyroid carcinoma. Among trials listed in clinical_trial_details: NCT07383246 (Phase III) evaluates a novel fibroblast activation protein inhibitor-guided precision surgical approach for newly diagnosed MTC (Cancer Institute of the Chinese Academy of Medical Sciences, recruiting); NCT07138716 investigates a cholecystokinin-derived radiotracer for PET/CT imaging in MTC; NCT06121271 (Phase II) examines radiolabeled peptide therapy in unlicensed indications including thyroid malignancies (University College London). GeneReviews notes that participation in clinical trials is an option referenced in major professional guidelines for individuals with advanced or metastatic disease. Active clinical trials for this condition are listed on ClinicalTrials.gov.